MedPath

Spirovant Sciences Doses First Patient in Phase 1/2 Trial of SP-101 Gene Therapy for Cystic Fibrosis

• Spirovant Sciences has initiated dosing in a Phase 1/2 clinical trial (SAAVe) evaluating SP-101, an inhaled gene therapy for cystic fibrosis (CF), in adults aged 18-65. • The SAAVe trial (NCT06526923) aims to enroll 15 CF patients with stable disease and a ppFEV1 between 50% and 100% to assess the safety and efficacy of SP-101. • SP-101 delivers a functional version of the CFTR gene to lung cells, potentially treating a range of CF patients, including those ineligible or insufficiently treated by CFTR modulators. • The trial combines SP-101 with doxorubicin to boost the gene therapy's activity and is currently recruiting at sites in Kansas City and New York City, with additional sites planned.

Spirovant Sciences has announced the dosing of the first patient in its Phase 1/2 clinical trial, SAAVe (NCT06526923), which is evaluating SP-101, an inhaled gene therapy for the treatment of cystic fibrosis (CF). The trial is currently recruiting participants aged 18 to 65 with stable CF and a percent predicted forced expiratory volume in one second (ppFEV1) between 50% and 100% at sites in Kansas City, Kansas, and New York City. Additional sites in Philadelphia and Boston are expected to join the study.

SAAVe Trial Details

The SAAVe trial aims to enroll 15 participants who will receive a single administration of SP-101 in combination with one of two doses of doxorubicin, a chemotherapy molecule intended to enhance the activity of the CF gene therapy candidate. The trial's design focuses on assessing the safety and potential efficacy of SP-101 in improving lung function and addressing the underlying genetic cause of CF.

Addressing Unmet Needs in CF Treatment

Cystic fibrosis is caused by mutations in the CFTR gene, leading to the production of thick, sticky mucus that damages organs and causes various disease symptoms. SP-101 is designed to deliver a functional version of the CFTR gene to lung cells, enabling them to produce a working CFTR protein. This approach is intended to be mutation-agnostic, potentially benefiting a broader range of CF patients, including those who are not eligible for or do not respond adequately to CFTR modulators, which address specific CF-causing mutations. Approximately 10% of people with CF cannot benefit from modulator therapy.

Expert Commentary

"The dosing of the first patient in the SAAVe Phase 1/2 clinical trial is a major milestone for Spirovant and for the cystic fibrosis patient community," said Roland Kolbeck, PhD, chief scientific officer of Spirovant. Claire Keating, MD, a study investigator at Columbia University Irving Medical Center in New York, added that this trial is "advancing a novel potential treatment pathway that moves us towards our goal of effectively treating people with CF who currently are not eligible for other highly effective therapies."
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Highlighted Clinical Trials

A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

NCT06526923RecruitingPhase 1
Spirovant Sciences, Inc.
Posted 9/16/2024

Related Topics

Marengo Therapeutics Advances Invikafusp Alfa into Phase 2 for PD-1 Resistant Tumors, Expands Trial to Europe

Marengo Therapeutics has dosed the first patient in the Phase 2 portion of the STARt-001 trial, evaluating invikafusp alfa in advanced anti-PD-1 resistant solid tumors.
Phase 1 data showed a 25% Overall Response Rate and a 50% Disease Control Rate in patients with PD-1 resistant tumors with high tumor mutation burden.

Cystic Fibrosis Foundation Invests $15 Million in Recode Therapeutics for CF Gene Editing

The Cystic Fibrosis Foundation is investing $15 million in Recode Therapeutics to advance gene-editing medicines for cystic fibrosis (CF) patients without effective treatment options.
Recode Therapeutics collaborates with Intellia Therapeutics, developing a strategy to alter the genetic code, creating a healthy CFTR gene version for functional protein production.

Sangamo's ST-503 Receives FDA Clearance for iSFN Clinical Trials

Sangamo Therapeutics' ST-503, an epigenetic regulator for chronic neuropathic pain in idiopathic small fiber neuropathy (iSFN), has received FDA clearance for its IND application.
A Phase 1/2 study is planned for mid-2025 to evaluate the safety and efficacy of a one-time intrathecal treatment using AAV vector technology targeting the SCN9A gene.

Spirovant Sciences Doses First Patient in Cystic Fibrosis Gene Therapy Trial

Spirovant Sciences has commenced its SAAVe Phase I/II study, dosing the first patient with SP-101, a gene therapy for cystic fibrosis, in combination with an augmenter.
SP-101, an inhalable adeno-associated virus (AAV) gene therapy, is engineered for tropism in human airway epithelia to enhance CFTR transgene expression.

Clarametyx Biosciences Advances CMTX-101 into Phase 2a Trial for Cystic Fibrosis

Clarametyx Biosciences has initiated a Phase 2a trial for CMTX-101, an antibody therapy targeting bacterial biofilms in cystic fibrosis patients with chronic pulmonary infections.
The Phase 2a trial is a double-blind, randomized, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, and immunogenicity of CMTX-101.

Calluna Pharma's CAL101 Demonstrates Favorable Safety Profile in Phase 1 Trial for Fibrotic Diseases

Calluna Pharma's CAL101, a first-in-class monoclonal antibody, has completed a Phase 1 trial showing a favorable safety, pharmacokinetic, and immunogenicity profile.
The randomized, double-blind, placebo-controlled study included 57 subjects and tested single and multiple ascending doses of CAL101, with mild to moderate adverse events.

Find Therapeutics Doses First Subject in Phase I Trial of FTX-101 for Chronic Optic Neuropathy

Find Therapeutics initiated a Phase I clinical trial of FTX-101, a potential treatment for chronic optic neuropathy, after receiving FDA approval.
The Phase I trial is a two-part study evaluating the safety, tolerability, and pharmacokinetics of FTX-101 versus placebo in healthy volunteers.

Clarametyx Advances CMTX-101 into Phase 2a for Cystic Fibrosis Lung Infections

Clarametyx Biosciences has initiated the Phase 2a portion of its clinical trial evaluating CMTX-101 for cystic fibrosis (CF)-associated pulmonary infections.
The Phase 2a study aims to enroll up to 41 adults with CF to assess the safety and tolerability of CMTX-101 as an adjunct to standard antibiotics.

First-in-Human Trial Successfully Assesses Novel Therapeutic Protein via CSF Analysis and Muscle Biopsy

A first-in-human, single ascending dose trial in San Antonio, TX, successfully evaluated a novel therapeutic protein (TP) in 48 healthy volunteers.
The study focused on cerebrospinal fluid (CSF) analysis to determine the TP's pharmacokinetic profile and binding at neuromuscular junctions.

Pierre Fabre and Scorpion Therapeutics Initiate Phase I/II Trial of EGFR Inhibitor PFL-241/STX-241 in NSCLC

Pierre Fabre and Scorpion Therapeutics have commenced a Phase I/II clinical trial for PFL-241/STX-241, a fourth-generation EGFR inhibitor.
The trial will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of PFL-241/STX-241 in advanced NSCLC patients.

Reference News

[1]
Trial of CF gene therapy SP-101 begins dosing, is still recruiting
cysticfibrosisnewstoday.com · Nov 18, 2024

A Phase 1/2 clinical trial for inhaled gene therapy SP-101 in CF patients, developed by Spirovant Sciences, has begun do...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy